Utilizing Interpretable AI to Distinguish prePMF From ET
December 10th 2023Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.
Watch
Odronextamab Continues to Appear Safe, Effective in Patients With R/R DLBCL
December 10th 2023In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Obe-cel Leads to Favorable Efficacy in R/R B-ALL With Varying Leukemic Burden
December 10th 2023Durable responses were seen with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia across bone marrow blast levels, with best efficacy and tolerability in those with less than 5% blasts.
Read More
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response
December 10th 2023Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.
Read More
Orca-T Demonstrates High RFS and OS in Intermediate/High-Risk MDS
December 10th 2023Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.
Read More
Study of Golidocitinib Finds Favorable Efficacy in Pretreated PTCL
December 10th 2023The JAK1 inhibitor golidocitinib led to responses in the challenging disease setting of relapsed/refractory peripheral T-cell lymphoma, as well as manageable hematologic toxicity, in the phase 2 JACKPOT8 study.
Read More
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
December 10th 2023Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
Read More
Single and Dual-Target D8 CAR T Cells Show Tolerability, Efficacy in R/R MM
December 10th 2023Investigators in the MCARTY study reported safety and high response rates in a small number of patients with relapsed/refractory multiple myeloma who received chimeric antigen receptor T-cell therapy designed with a new process to target the D8 binder, meant to improve efficacy in targeting BCMA.
Read More
Pirtobrutinib Shows Durable Responses After Covalent BTKi Treatment in CLL/SLL
December 10th 2023Updated results from the phase 1/2 BRUIN study show a high objective response rate and promising progression-free survival outcomes with pirtobrutinib following prior covalent Bruton tyrosine kinase inhibition in patients with chronic lymphocytic leukemia.
Read More
Outpatient CAR T-Cell Therapy Process Improved by Virtual Care Platform
December 10th 2023Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.
Read More
Zanubrutinib Induces Sustained PFS Benefit in Relapsed/Refractory CLL/SLL
December 10th 2023According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL
December 10th 2023Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
Read More
An All-Oral Revumenib Combination Achieves 100% ORR Patients with R/R AML
December 9th 2023Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Read More
Real-World Analysis Shows Similar Safety, Efficacy With Teclistamab in RRMM
December 9th 2023The retrospective analysis demonstrated comparable outcomes with teclistamab from the phase 2 MajesTEC-1 trial, highlighting the need for close monitoring and supportive care in patients treated for their relapsed or refractory multiple myeloma.
Read More
Neoadjuvant Nivolumab/Carboplatin/Paclitaxel Delivers High pCR Rates in Early-Stage TNBC
December 9th 2023Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.
Read More
Survival Benefit With Neoadjuvant Pembro/Chemo, Adjuvant Pembro Upheld in High-Risk Early TNBC
December 9th 2023Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.
Read More
No Significant pCR Improvement With Neoadjuvant HP/Chemo Plus Atezolizumab in HER2+ Breast Cancer
December 8th 2023The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
Read More